A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Georgia's Online Cancer Information Center

Find A Clinical Trial

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Status
Active
Cancer Type
Solid Tumor
Trial Phase
Phase I
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT05536141
Protocol IDs
ARC-20 (primary)
NCI-2023-02610
2024-519142-70-00
Study Sponsor
Arcus Biosciences, Inc.

Summary

The purpose of this study is to evaluate the safety and tolerability of:

- casdatifan when taken alone in participants with advanced solid tumor malignancies
and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and

- casdatifan monotherapy and casdatifan in combination with cabozantinib or
zimberelimab or zimberelimab and ipilimumab in participants with ccRCC in the dose
expansion stage.

Eligibility

  1. Must have at least one measurable lesion per RECIST guidance
  2. Eastern Cooperative Oncology Group (ECOG) performance status score of = 1
  3. Disease-specific criteria for dose escalation:
  4. Participants may have any pathologically confirmed solid tumor type where no other treatment options are available
  5. Creatinine clearance = 40 mL/min Disease-specific criteria for dose-expansion:
  6. Histologically confirmed ccRCC
  7. Creatinine clearance = 40 mL/min Key

Treatment Sites in Georgia

Winship Cancer Institute of Emory University


1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.